Plain-English translation of NCT06976216 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer's Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a large research study testing a new medication called + to see if it can help improve memory and thinking abilities in people with mild to moderate Alzheimer's disease. About 586 people will participate, and half will receive the medication while the other half will receive a placebo (a pill with no active medicine) to compare results. Researchers will carefully track how the treatment affects cognitive symptoms over time.
Alzheimer's disease gradually damages memory and thinking abilities, and current treatments have limited effectiveness. This study aims to find out whether this new medication could offer better help for people in the early-to-middle stages of the disease.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll be randomly assigned to either take the new medication or a placebo, and neither you nor the research team will know which one you're receiving. You'll attend multiple study visits where researchers will test your memory and thinking, check your overall health, and monitor how you're responding to the treatment. A trusted family member or friend will need to participate with you at visits and help ensure you're taking the study medication as directed.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States